Norges Bank
PTGX icon

Norges Bank’s Protagonist Therapeutics PTGX Stock Holding History

Norges Bank’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-148,700
Closed -$1.62M – 2150
2022
Q4 		$1.62M Buy
+148,700
New +$1.25M ﹤0.01% 1997
2021
Q1 		– Sell
-11,160
Closed -$225K – 2185
2020
Q4 		$225K Hold
11,160
– – ﹤0.01% 2102
2020
Q3 		$218K Buy
+11,160
New +$209K ﹤0.01% 2116

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank's PTGX Position: Q1 2023 in Review

Norges Bank sold out of Protagonist Therapeutics (PTGX) in Q1 2023, closing a stake of 148,700 shares — an estimated $1.62M sold.

Norges Bank first reported a position in PTGX in Q3 2020 and held it in 3 quarters. The position peaked at $1.62M in Q4 2022. 137 funds tracked by Wall St. Rank hold PTGX as of Q1 2023.

  • Norges Bank reported no remaining Protagonist Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Norges Bank sold 148,700 Protagonist Therapeutics shares in Q1 2023, an estimated $1.62M.
  • Norges Bank first reported a position in Protagonist Therapeutics in Q3 2020 and held it in 3 quarters.
  • Norges Bank's Protagonist Therapeutics position peaked at $1.62M in Q4 2022.
  • 137 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2023.

Based on Norges Bank's 13F filing for Q1 2023, filed 15 May 2023.